Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China. more
Time Frame | ADAG | Sector | S&P500 |
---|---|---|---|
1-Week Return | -17% | -3.39% | 0.2% |
1-Month Return | -6.25% | -1.92% | 2.72% |
3-Month Return | -9.87% | -10.54% | 7.31% |
6-Month Return | -16.33% | -4.47% | 10.44% |
1-Year Return | 43.34% | 4.06% | 27.53% |
3-Year Return | -72.04% | 0.94% | 30.88% |
5-Year Return | -93% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 480.00K | 480.00K | 10.18M | 9.29M | 18.11M | [{"date":"2019-12-31","value":2.65,"profit":true},{"date":"2020-12-31","value":2.65,"profit":true},{"date":"2021-12-31","value":56.18,"profit":true},{"date":"2022-12-31","value":51.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | 480.00K | 480.00K | 10.18M | 9.29M | 18.11M | [{"date":"2019-12-31","value":2.65,"profit":true},{"date":"2020-12-31","value":2.65,"profit":true},{"date":"2021-12-31","value":56.18,"profit":true},{"date":"2022-12-31","value":51.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 19.65M | 19.65M | 82.54M | 93.21M | 41.83M | [{"date":"2019-12-31","value":21.08,"profit":true},{"date":"2020-12-31","value":21.08,"profit":true},{"date":"2021-12-31","value":88.55,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":44.88,"profit":true}] |
Operating Income | (19.17M) | (19.17M) | (72.36M) | (83.92M) | (23.72M) | [{"date":"2019-12-31","value":-1916965000,"profit":false},{"date":"2020-12-31","value":-1916965000,"profit":false},{"date":"2021-12-31","value":-7236408900,"profit":false},{"date":"2022-12-31","value":-8392068300,"profit":false},{"date":"2023-12-31","value":-2371986600,"profit":false}] |
Total Non-Operating Income/Expense | 3.52M | 1.54M | 600.17K | 4.09M | 9.64M | [{"date":"2019-12-31","value":36.53,"profit":true},{"date":"2020-12-31","value":15.96,"profit":true},{"date":"2021-12-31","value":6.23,"profit":true},{"date":"2022-12-31","value":42.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (16.43M) | (16.43M) | (71.48M) | (79.51M) | (17.25M) | [{"date":"2019-12-31","value":-1643230800,"profit":false},{"date":"2020-12-31","value":-1643230800,"profit":false},{"date":"2021-12-31","value":-7147632200,"profit":false},{"date":"2022-12-31","value":-7951279200,"profit":false},{"date":"2023-12-31","value":-1725496200,"profit":false}] |
Income Taxes | 861.57K | 3.16K | 1.70M | 459.06K | 1.69M | [{"date":"2019-12-31","value":50.63,"profit":true},{"date":"2020-12-31","value":0.19,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.98,"profit":true},{"date":"2023-12-31","value":99.4,"profit":true}] |
Income After Taxes | (17.29M) | (16.44M) | (73.18M) | (79.97M) | (18.95M) | [{"date":"2019-12-31","value":-1729388000,"profit":false},{"date":"2020-12-31","value":-1643547200,"profit":false},{"date":"2021-12-31","value":-7317793500,"profit":false},{"date":"2022-12-31","value":-7997184700,"profit":false},{"date":"2023-12-31","value":-1894637000,"profit":false}] |
Income From Continuous Operations | (16.43M) | (16.43M) | (73.18M) | (79.97M) | (18.95M) | [{"date":"2019-12-31","value":-1643230800,"profit":false},{"date":"2020-12-31","value":-1643230800,"profit":false},{"date":"2021-12-31","value":-7317793500,"profit":false},{"date":"2022-12-31","value":-7997184700,"profit":false},{"date":"2023-12-31","value":-1894637000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (17.29M) | (16.44M) | (73.18M) | (79.97M) | (18.95M) | [{"date":"2019-12-31","value":-1729388000,"profit":false},{"date":"2020-12-31","value":-1643547200,"profit":false},{"date":"2021-12-31","value":-7317793500,"profit":false},{"date":"2022-12-31","value":-7997184700,"profit":false},{"date":"2023-12-31","value":-1894637000,"profit":false}] |
EPS (Diluted) | (1.79) | (3.20) | (1.95) | (3.21) | - | [{"date":"2019-12-31","value":-179.48,"profit":false},{"date":"2020-12-31","value":-320.41,"profit":false},{"date":"2021-12-31","value":-195,"profit":false},{"date":"2022-12-31","value":-321,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
ADAG | |
---|---|
Cash Ratio | 2.42 |
Current Ratio | 2.50 |
Quick Ratio | 2.50 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ADAG | |
---|---|
ROA (LTM) | -19.59% |
ROE (LTM) | -45.70% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ADAG | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.44 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.56 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ADAG | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 113.97 |
P/B | 1.64 |
Price/FCF | NM |
EV/R | 22.17 |
EV/Ebitda | 1.12 |
Adagene Inc (ADAG) share price today is $2.1
Yes, Indians can buy shares of Adagene Inc (ADAG) on Vested. To buy Adagene Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ADAG stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Adagene Inc (ADAG) via the Vested app. You can start investing in Adagene Inc (ADAG) with a minimum investment of $1.
You can invest in shares of Adagene Inc (ADAG) via Vested in three simple steps:
The 52-week high price of Adagene Inc (ADAG) is $4.38. The 52-week low price of Adagene Inc (ADAG) is $1.6.
The price-to-earnings (P/E) ratio of Adagene Inc (ADAG) is
The price-to-book (P/B) ratio of Adagene Inc (ADAG) is 1.64
The dividend yield of Adagene Inc (ADAG) is 0.00%
The market capitalization of Adagene Inc (ADAG) is $108.46M
The stock symbol (or ticker) of Adagene Inc is ADAG